Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to sharpen prognosis tools for rare blood cancer

NCT ID NCT05911802

Knowledge-focused Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 500 people with Waldenström macroglobulinemia, a rare blood cancer, to check how well current scoring systems predict survival and treatment response. Researchers will track patients over time, including those without symptoms, to refine these tools. The goal is to help doctors make better treatment decisions and design faster clinical trials for new therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict disease progression and tailor treatments for Waldenström patients, potentially improving survival and quality of life.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly provide new therapies. Results may not apply to all patient groups or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

250 symptomatic patients and 250 asymptomatic patients will be prospectively enrolled

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with WM, fulfilling the diagnostic criteria defined at the 2nd Workshop on WM. * Patient in whom follow-up is available until at least 01/01/2020. Each participating center should not enroll more 10% of patients lost to follow-up. * Patient for whom a minimum annual follow-up is planned until 2024. * Having given their consent for this study Exclusion Criteria: * Patient with other chronic lymphoid malignancy. Special attention will be paid to exclude other lymphoplasmacytic proliferations, especially marginal zone lymphoma. * Patient with histological transformation in a diffuse large B-cell lymphoma or any other lymphoma at the time of the initiation of the 1st treatment. * No consent for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prognostic index are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prognostic index Waldenstrom's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AMIENS - CH Amiens Picardie Site Sud

    NOT_YET_RECRUITING

    Amiens, 80054, France

  • APHP - Hôpital Pitié Salpêtrière - Hématologie

    NOT_YET_RECRUITING

    Paris, 75651, France

  • Angers Chu

    NOT_YET_RECRUITING

    Angers, 49933, France

  • Clermont-Ferrand - Chu Estaing

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • Institut Bergonie

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

  • Institut Paoli Calmette

    NOT_YET_RECRUITING

    Marseille, 130009, France

  • LENS - GHT Artois

    NOT_YET_RECRUITING

    Lens, 62300, France

  • LIBOURNE - Hôpital Robert Boulin

    NOT_YET_RECRUITING

    Libourne, 33505, France

  • LILLE GHICL - Hôpital Saint Vincent de Paul

    RECRUITING

    Lille, 59000, France

  • Le Mans CH

    NOT_YET_RECRUITING

    Le Mans, France

  • POITIERS - Hématologie et Thérapie Cellulaire

    NOT_YET_RECRUITING

    Poitiers, 86021, France

  • Reims Chu

    NOT_YET_RECRUITING

    Reims, 51092, France

  • Strasbourg - Icans

    NOT_YET_RECRUITING

    Strasbourg, 67033, France

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    NOT_YET_RECRUITING

    Toulouse, 31059, France

  • VERSAILLES - Hôpital André Mignot

    NOT_YET_RECRUITING

    Versailles, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.